Author

Marion Masitsa Malenge

Observed names: Marion M. Malenge, Marion Malenge

Institution: Oncoinvent (Norway)

Observed institutions: Oslo University Hospital, University of Oslo, Nordic Nanovector (Norway), Oncoinvent (Norway)

ORCID: 0009-0005-2249-1060

Observed ORCID: 0009-0005-2249-1060

OpenAlex ID: A5064819566

Ra‐224 labeling of calcium carbonate microparticles for internal α‐therapy: Preparation, stability, and biodistribution in mice

2018 · Sara Westrøm, Marion Malenge, et al. · Journal of Labelled Compounds and Radiopharmaceuticals · 50

Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma

2018 · Ada H. V. Repetto‐Llamazares, Marion M. Malenge, et al. · European Journal Of Haematology · 23

177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

2020 · Marion M. Malenge, Sebastian Patzke, et al. · Journal of Nuclear Medicine · 14

Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma

2024 · Kim Lindland, Marion Masitsa Malenge, et al. · Scientific Reports · 11

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al. · Molecular Cancer Therapeutics · 6

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro

2022 · Marion M. Malenge, Astri Fjelde Maaland, et al. · PLoS ONE · 3

Table S2 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S2 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Data from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S3 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Figure S1 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S3 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S4 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Table S1 from Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy

2025 · Kim Lindland, Sara Westrøm, et al.

Combination of anti-CD37 radioimmunotherapy with anti-CD20 immunotherapy and small molecule inhibitors to improve therapy of non- Hodgkin lymphoma

2020 · Marion Masitsa Malenge · NORA - Norwegian Open Research Archives

Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model

2019 · Marion Masitsa Malenge, Anne Hansen Ree, et al. · Journal of Nuclear Medicine

Works count: 16

Citation count: 107

H-index: 5

I10-index: 4